Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands
Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
BMJ Open. 2021 Oct 18;11(10):e049349. doi: 10.1136/bmjopen-2021-049349.
Current evaluation of patients suspected of a non-ST-elevation acute coronary syndrome (NSTE-ACS) involves the use of algorithms that incorporate clinical information, electrocardiogram (ECG) and high-sensitivity cardiac troponins (hs-troponins). While primarily designed to rule out NSTE-ACS safely, these algorithms can also be used for rule in of NSTE-ACS in some patients. Still, in a substantial number of patients, these algorithms do not provide a conclusive work-up. These patients often present with an atypical clinical profile and low-range positive hs-troponin values without a characteristic rise or fall pattern. They represent a heterogeneous group of patients with various underlying conditions; only a fraction (30%-40%) will eventually be diagnosed with a myocardial infarction. Uncertainty exists about the optimal diagnostic strategy and their management depends on the clinical perspective of the treating physician ranging from direct discharge to admission for invasive coronary angiography. Coronary CT angiography (CCTA) is a non-invasive test that has been shown to be safe, fast and reliable in the evaluation of coronary artery disease. In this study, we will determine the usefulness of CCTA in patients with acute chest pain and low-range positive hs-troponin values.
A prospective, double-blind, observational, multicentre study conducted in the Netherlands. Patients aged 30-80 years presenting to the emergency department with acute chest pain and a suspicion of NSTE-ACS, a normal or non-diagnostic ECG and low-range positive hs-troponins will be scheduled to undergo CCTA. The primary outcome is the diagnostic accuracy of CCTA for the diagnosis of NSTE-ACS at discharge, in terms of sensitivity and negative predictive value.
This study was approved by the Medical Research Ethics Committee of Erasmus Medical Center in Rotterdam, the Netherlands (registration number MEC-2017-506). Written informed consent to participate will be obtained from all participants. This study's findings will be published in a peer-reviewed journal.
ClinicalTrials.gov (NCT03129659).
目前,对疑似非 ST 段抬高型急性冠状动脉综合征(NSTE-ACS)的患者进行评估时,需要使用整合临床信息、心电图(ECG)和高敏心肌肌钙蛋白(hs-troponin)的算法。这些算法主要用于安全排除 NSTE-ACS,但在某些患者中也可用于确诊 NSTE-ACS。然而,在相当数量的患者中,这些算法并不能提供明确的检查结果。这些患者通常表现为非典型的临床特征,hs-troponin 值处于低值阳性范围,且无特征性升高或降低模式。他们代表了一组具有不同潜在疾病的异质患者;只有一小部分(30%-40%)最终会被诊断为心肌梗死。对于最佳诊断策略,存在不确定性,其管理取决于治疗医生的临床观点,范围从直接出院到进行有创冠状动脉造影。冠状动脉 CT 血管造影(CCTA)是一种安全、快速且可靠的评估冠状动脉疾病的非侵入性检查。在这项研究中,我们将确定 CCTA 在急性胸痛和低值阳性 hs-troponin 值患者中的应用价值。
这是一项在荷兰进行的前瞻性、双盲、观察性、多中心研究。将年龄在 30-80 岁、因急性胸痛就诊于急诊科且怀疑为 NSTE-ACS、心电图正常或无诊断意义、hs-troponin 值低值阳性的患者纳入研究,并安排进行 CCTA。主要结局是 CCTA 在出院时诊断 NSTE-ACS 的诊断准确性,包括敏感性和阴性预测值。
本研究已获得荷兰鹿特丹伊拉斯谟医疗中心医学伦理委员会的批准(注册号:MEC-2017-506)。所有参与者均将获得书面知情同意书。本研究的结果将发表在同行评议的期刊上。
ClinicalTrials.gov(NCT03129659)。